N Vakil, D Vaira - JAMA, 2008 - Am Med Assoc A less frequently used regimen is quadruple therapy, consisting of bismuth plus
metronidazole, tetracycline, and a PPI administered for 10 days. It has been
suggested as an alternative to PPI triple therapy. The most recent US study ... Cited by 7 - Related articles - All 2 versions
BJ Egan, L Marzio, H O'Connor, C O'Morain - Helicobacter, 2008 - interscience.wiley.com Antibiotic resistance has resulted in unsatisfactory eradication results with
dual and now triple therapy in many countries. Newer antibiotics and changes in
dosing and duration of therapy may overcome resistant strains but may only ... Cited by 5 - Related articles - All 5 versions
AS Essa, JR Kramer, DY Graham, G Treiber - Helicobacter, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 4 - Related articles - All 4 versions
CA O'Morain, JPA O'Connor - Nature Clinical Practice Gastroenterology & …, 2008 - nature.com Nature Clinical Practice Gastroenterology & Hepatology will deliver timely
interpretations of key research developments, translating the latest findings into ... Cited by 2 - Related articles - All 3 versions
N Vakil - Am J Gastroenterol, 2009 - nature.com Treatment of Helicobacter pylori infection has become a problem in many clinical
settings. Eradication rates are at the lowest levels seen in the past decade and
are likely to fall further as antimicrobial resistance becomes more ... Cited by 2 - Related articles - All 5 versions
B Marshall - Annals of Internal Medicine, 2008 - Am Coll Physicians First, after a decade of clarithromycin-based treatments and continued
widespread use of long-acting macrolides in general practice, 10% to 15% of H.
pylori strains are resistant de novo to clarithromycin (3). As a result, ... Cited by 1 - Related articles - BL Direct - All 4 versions
DY Graham - Clinical Gastroenterology and Hepatology, 2009 - Elsevier Although recent trials performed primarily in Italy have identified drug
combinations with improved results for empirically administered therapy, 9
annually hundreds if not thousands of patients fail empirically ... Cited by 2 - Related articles - All 27 versions
G Labbé, 2009 - uwspace.uwaterloo.ca Page 1. Dynamics and Inhibition of Class II Fructose 1,6-bisphosphate Aldolase by
Geneviève Labbé A thesis presented to the University of Waterloo ... Related articles - View as HTML - All 3 versions
